Dapagliflozin/Saxagliptin is a combination medication designed to help manage diabetes mellitus, a chronic condition that affects how the body handles glucose (sugar). This medication combines two active ingredients, dapagliflozin/Saxagliptin, to address different aspects of diabetes control. Dapagliflozin/Saxagliptin sold under the brand name Qtern.[2][3] It is a combination of dapagliflozin and saxagliptin.[2][3] It is taken by mouth.[2][3]
| Combination of | |
|---|---|
| Dapagliflozin | SGLT-2 inhibitor |
| Saxagliptin | Dipeptidyl peptidase-4 inhibitor |
| Clinical data | |
| Trade names | Qtern |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels).[3]
Dapagliflozin/saxagliptin was approved for medical use in the European Union in July 2016, and in the United States in February 2017.[3][4]
Synergistic Mechanism of Action edit
Dual-Action Approach: The combination of dapagliflozin and saxagliptin provides a dual-action approach to diabetes management. Dapagliflozin addresses excess glucose in the urine, reducing blood glucose levels independently of insulin, while saxagliptin fine-tunes glycemic control by modulating incretin dynamics.
Comprehensive Glycemic Control: By targeting different pathways involved in glucose regulation, the combination aims to achieve comprehensive glycemic control. This is particularly beneficial for individuals with type 2 diabetes who may have varying degrees of insulin resistance and impaired incretin function.
Potential Cardiovascular and Renal Benefits: Beyond glycemic control, both dapagliflozin and saxagliptin have shown potential cardiovascular and renal benefits in clinical studies. The combination's dual mechanism may contribute to these additional positive outcomes, providing a holistic approach to diabetes care.
Medical uses edit
In the United States dapagliflozin/saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[2]
In the European Union it is indicated in adults aged 18 years and older with type 2 diabetes mellitus:
Adverse effects edit
- Hypoglycemia (low blood sugar): While less common with dapagliflozin alone, it can occur, especially if used in conjunction with other antidiabetic medications.
- Dehydration: Excessive loss of fluids through increased urine output may lead to dehydration, particularly if fluid intake is insufficient.
- Genital Infections: There may be an increased risk of genital yeast infections in both men and women.
- Pancreatitis: In rare cases, saxagliptin has been associated with inflammation of the pancreas (pancreatitis).
- Allergic Reactions: Some individuals may experience allergic reactions, such as rash or swelling.
- Hypoglycemia: The risk of hypoglycemia may be present, especially if the combination is used with other antidiabetic medications.
- Renal Function Changes: Both dapagliflozin and saxagliptin may affect kidney function, and regular monitoring is recommended.
Use in Pregnancy edit
- When it comes to combination therapy with dapagliflozin and saxagliptin, the cumulative effects on pregnancy and fetal development need careful consideration.
- The safety of using this combination during pregnancy has not been extensively studied, and therefore, caution is advised.
References edit
- ^ a b "Dapagliflozin / saxagliptin (Qtern) Use During Pregnancy". Drugs.com. 28 June 2019. Retrieved 14 July 2020.
- ^ a b c d e "Qtern- dapagliflozin and saxagliptin tablet, film coated". DailyMed. 24 January 2020. Retrieved 14 July 2020.
- ^ a b c d e f g h "Qtern EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 14 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Drug Approval Package: Qtern (dapagliflozin and saxagliptin)". U.S. Food and Drug Administration (FDA). 10 October 2018. Retrieved 14 July 2020.
External links edit
- "Dapagliflozin propanediol". Drug Information Portal. U.S. National Library of Medicine.
- "Saxagliptin". Drug Information Portal. U.S. National Library of Medicine.
- "Dapagliflozin". MedlinePlus.
- "Saxagliptin". MedlinePlus.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |